Fulgent Genetics, Inc.

FLGT Healthcare Diagnostics & Research

Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.

19.81 1.53 −7.17%
Market cap
$587.2M
P/E
0.0×
Fwd P/E
−5.8×
Dividend yield
—
F-score
4/9
Altman Z
5.63
Beneish M
−2.35
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 2 4 7

+8 more TTM periods

ROE
(8.01%) (6.81%) (5.41%) (3.81%)
ROA
(7.37%) (6.25%) (4.97%) (3.51%)
ROIC
(10.34%) (8.62%) (7.39%) (5.96%)
Return on Tangible Assets
(17.01%) (14.61%) (10.47%) (7.86%)
Average Days of Receivables
73.17 78.93 95.88 82.34
Free Cash Flow per Share
(3.71) (3.66) (4.04) (0.65)
Free Cash Flow
(103.78) (113.16) (124.21) (19.84)
Other line items

Show all line items

Columns are period end dates